a study of obinutuzumab, polatuzumab vedotin, and lenalidomide in relapsed or refractory follicular lymphoma (fl) and rituximab in combination with polatuzumab vedotin and lenalidomide in relapsed or refractory diffuse large b-cell lymphoma (dlbcl)

Conditions: Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Summary: this study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and lenalidomide in participants with relapsed or refractory (r/r) follicular lymphoma (fl) and rituximab in combination with polatuzumab vedotin and lenalidomide in participants with r/r diffuse large b-cell lymphoma (dlbcl), followed by post-induction treatment with obinutuzumab in combination with lenalidomide in participants with fl who achieve a complete response (cr), partial response (pr), or stable disease (sd) at end of induction (eoi) and post-induction treatment with rituximab plus lenalidomide in participants with dlbcl who achieve a cr or pr at eoi.


Eligibility criteria:
inclusion criteria: * age greater than or equal to (\>/=) 18 years * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * for obinutuzumab in combination with polatuzumab vedotin and lenalidomide (g + pola + len) treatment group: r/r fl after treatment with at least one prior chemoimmunotherapy regimen that included an anti-cd20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigator * for rituximab in combination with polatuzumab vedotin and lenalidomide (r + pola + len) treatment group: r/r dlbcl after treatment with at least one prior chemoimmunotherapy regimen that included an anti-cd20 monoclonal antibody in patients who are not eligible for autologous stem-cell transplantation or who have experienced disease progression following treatment with high-dose chemotherapy plus autologous stem-cell transplantation * histologically documented cd20-positive b-cell lymphoma as determined by the local laboratory * fluorodeoxyglucose (fdg)-avid lymphoma (i.e., positron emission tomography (pet)-positive lymphoma) * at least one bi-dimensionally measurable lesion * agreement to remain abstinent or use adequate contraception, among women or men of childbearing potential exclusion criteria: * grade 3b follicular lymphoma * history of transformation of indolent disease to diffuse large b-cell lymphoma (dlbcl) * known cd20-negative status at relapse or progression * central nervous system (cns) lymphoma or leptomeningeal infiltration * prior allogeneic stem-cell transplantation (sct), or autologous sct within 100 days prior to day 1 of cycle 1 * current use of systemic immunosuppressant(s), or prior anti-cancer therapy to include: lenalidomide, fludarabine, or alemtuzumab within 12 months; radioimmunoconjugate within 12 weeks; mab or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to day 1 of cycle 1 * active infection * positive for human immunodeficiency virus (hiv) or hepatitis b or c * receipt of a live virus vaccine within 28 days prior to day 1 of cycle 1 * poor hematologic, renal, or hepatic function * pregnant or lactating women * life expectancy less than (\<) 3 months